Orqis^® Medical Corporation is a privately held, clinical-stage medical device company that is applying its discovery of a new hemodynamic principle to change the way congestive heart failure is treated. Founded in 1997, Orqis Medical is headquartered in Lake Forest , California .

Customarily, when there’s an injury to the body, the injured area is allowed to rest to better facilitate recovery. However, when it comes to treating CHF, today’s medical practices either make the heart work harder or potentially atrophy the heart by assigning its function to a device.

The CRS™ therapy is the first cardiac recovery system for patients with CHF and the only treatment that seeks to create a “rest-to-recovery” environment for the heart. Orqis Medical’s first product, the Cancion ® CRS™ therapy, is currently under clinical investigation in the United States for use in-hospital for acute CHF patients who are no longer responding to standard medical therapies. The CRS therapy is designed to break the vicious cycle of heart failure, allowing the heart to rest and recover while the patient’s clinical status improves.